She did not release a statement with the approval — noteworthy considering it was the first new Alzheimer’s drug in nearly two decades — or appear in the agency’s briefing with top officials after the announcement.
"It's an incredible loss of confidence in transparency around the agency, in particular the drug approval process”
"It's an incredible loss of confidence in transparency around the agency, in particular the drug approval process”
Controversial drug approval stokes concern about lack of a permanent FDA chief
Janet Woodcock did not release a statement with the approval — noteworthy considering it was the first new Alzheimer’s drug in nearly two decades.
www.politico.com